Homeopathic Drug Pertussinum Recalled Due to Manufacturing Deviations
Washington Homeopathic Products is recalling Pertussinum in multiple potencies nationwide due to manufacturing practice deviations. Affected lot numbers are 18829, 20142, and 25410.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. This is a voluntary, firm-initiated precautionary recall due to manufacturing practice deviations, meeting the criteria for moderate-severity voluntary precautionary recalls.
Plain-English summary
Washington Homeopathic Products, Inc. is voluntarily recalling Pertussinum in potencies 19C, 30C, 200C, and 1M as liquid pellets. The recall affects 375 glass amber bottles with lot numbers 18829, 20142, and 25410 that were distributed nationwide.
The recall was initiated due to manufacturing practice deviations identified by the firm. The Food and Drug Administration classified this as a Class II recall. The firm initiated the recall on May 13, 2022, and it was terminated on May 25, 2023.
Consumers with affected products should contact Washington Homeopathic Products, Inc. for instructions on how to handle their affected purchases.
The recalled product
- Product
- Pertussinum, Potency: 19C, 30C, 200C, 1M, Liquid Pellets, OTC, Washington Homeopathic Products, 260 JR Hawvermale Way, Berkeley Springs, WV 25411
- Manufacturer
- Washington Homeopathic Products, Inc.
- Category
- Drug — Homeopathic
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot# 18829
- 20142
- 25410
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27